Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Novo Nordisk says it is aware of 10 deaths from compounded weight-loss drug copies
03:13am, Wednesday, 06'th Nov 2024
Novo Nordisk is aware of 100 hospitalizations and 10 deaths resulting from people taking compounded copies of its popular weight-loss and diabetes drugs, the drugmaker's finance chief said on Wednesda
Novo Nordisk Q3 numbers boosted by Wegovy beat
03:06am, Wednesday, 06'th Nov 2024
Novo Nordisk (NYSE:NVO) reported better-than-expected third-quarter sales of its weight-loss drug Wegovy, reaching $2.49 billion, exceeding analyst expectations of $2.29 billion and increasing 48% fr
Novo Nordisk's Wegovy Sales Beat Expectations
02:26am, Wednesday, 06'th Nov 2024
The pharmaceutical giant narrowed its full-year guidance after its blockbuster Wegovy weight-loss drug beat sales expectations in the third quarter.
Novo Nordisk quarterly profit meets expectations as Wegovy maker narrows full-year guidance
01:46am, Wednesday, 06'th Nov 2024
Novo Nordisk quarterly profit meets expectations as Wegovy maker narrows full-year guidance
Bagsværd, 6 November 2024 - Financial report for the period 1 January 2024 to 30 September 2024
Novo Nordisk Q3 in line with expectations, narrows FY guidance range
01:36am, Wednesday, 06'th Nov 2024
Weight-loss and diabetes drugmaker Novo Nordisk on Wednesday posted third-quarter operating profit in line with expectations and narrowed its full-year sales and profit guidance range.
Bagsværd, 6 November 2024 - Financial report for the period 1 January 2024 to 30 September 2024
Novo Nordisk Earnings Are Soon. It's All About Weight-Loss Drug Sales.
04:30pm, Tuesday, 05'th Nov 2024
Investors want assurance the new GLP-1 weight-loss medicines can live up to their blockbuster expectations.
What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings?
04:00pm, Tuesday, 05'th Nov 2024
Let us look at five large biotech and generic drug companies, NVO, GILD, MRNA, VTRS and TEVA, which are gearing up for their earnings releases this week.
Earnings Exchange: Supermicro, Novo Nordisk, CVS Health
02:34pm, Tuesday, 05'th Nov 2024
Steve Grasso, CEO of Grasso Global, joins CNBC's 'The Exchange' to discuss outlooks on three stocks: Supermicro, Novo Nordisk, and CVS Health.
PFE or NVO: Which Is the Better Value Stock Right Now?
12:41pm, Tuesday, 05'th Nov 2024
Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Pfizer (PFE) or Novo Nordisk (NVO). But which of these two stocks presents investors with the better
Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts?
10:00am, Tuesday, 05'th Nov 2024
Novo Nordisk AS NVO will report third-quarter earnings on Wednesday. Wall Street expects 88 cents in EPS and $10.49 billion in revenues when the company reports after market hours.
Novo Nordisk A/S - share repurchase programme
08:37am, Tuesday, 05'th Nov 2024
Bagsværd, Denmark, 5 November 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Coun
Hims & Hers Stock Jumps. A Generic Version of Novo Nordisk Diabetes Drug Is Close.
08:30am, Tuesday, 05'th Nov 2024
The telehealth company will launch a generic version of Novo's type 2 diabetes drug liraglutide in 2025.
Catalent misses Q1 revenue estimates ahead of $16.5 bln deal close with Novo Holdings
08:25am, Tuesday, 05'th Nov 2024
Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.
